Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aplindore. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 13/20 | 0.68 |
| ▸ | DRD4 | P21917 | 7/20 | 0.68 |
| ▸ | DRD3 | P35462 | 7/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aplindore SCHEMBL3192098 | 1.00 | DRD2 (0.68) | DRD2DRD4DRD3ALDH1A1PARP1 | |
| Aplindore SCHEMBL29359212 | 1.00 | DRD2 (0.68) | DRD2DRD4DRD3ALDH1A1PARP1 | |
| Aplindore SCHEMBL1231153 | 0.93 | DRD2 (0.60) | DRD2DRD4DRD3ALDH1A1PARP1 | |
| Aplindore SCHEMBL29470967 | 0.93 | DRD2 (0.60) | DRD2DRD4DRD3ALDH1A1PARP1 | |
| Aplindore SCHEMBL5954695 | 0.93 | DRD2 (0.60) | DRD2DRD4DRD3ALDH1A1PARP1 | |
| SCHEMBL5957109 | 0.91 | DRD2 (0.58) | DRD2DRD4DRD3ALDH1A1PARP1 | |
| SCHEMBL5957081 | 0.90 | DRD2 (0.55) | DRD2DRD4DRD3ALDH1A1MEN1 | |
| SCHEMBL5957139 | 0.90 | DRD2 (0.55) | DRD2DRD4DRD3ALDH1A1MEN1 | |
| Aplindore SCHEMBL3029385 | 0.88 | DRD2 (0.54) | DRD2DRD4DRD3ALDH1A1PARP1 | |
| SCHEMBL13481964 | 0.87 | DRD2 (0.52) | DRD2DRD4DRD3ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 885 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060123-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2021-03-04 | — | — | US | claimed |
| US-20180161392-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2018-06-14 | — | — | US | claimed |
| EP-2825208-B1 | P75NTR NEUROTROPHIN BINDING PROTEIN FOR THERAPEUTIC USE | LEVICEPT LTD (GB) | 2017-05-17 | — | — | EP | claimed |
| EP-2961730-A2 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XenoPort, Inc. (US) | 2016-01-06 | — | — | EP | claimed |
| US-20150158809-A9 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XENOPORT, INC. (US) | 2015-06-11 | — | — | US | claimed |
| US-20150037335-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2015-02-05 | — | — | US | claimed |
| EP-2825208-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | Levicept Ltd. (GB) | 2015-01-21 | — | — | EP | claimed |
| EP-2175728-B1 | SODIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2014-09-10 | — | — | EP | claimed |
| WO-2014134005-A2 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XENOPORT, INC. (US) | 2014-09-04 | — | — | WO | claimed |
| US-20140243544-A1 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XENOPORT, INC. (US) | 2014-08-28 | — | — | US | claimed |
| US-8062870-B2 | Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs | XENOPORT, INC. (US) | 2011-11-22 | — | — | US | claimed |
| US-20090111837-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN | PFIZER INC. | 2009-04-30 | — | — | US | claimed |
| CN-101146539-A | Use of pde7 inhibitors for the treatment of neuropathic pain | PFIZER LTD (GB) | 2008-03-19 | — | — | CN | claimed |
| EP-1855686-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN | Pfizer Limited (GB) | 2007-11-21 | — | — | EP | claimed |
| EP-1375503-B1 | Dioxino derivatives and their use as dopanine agonists | WYETH CORP (US) | 2006-12-27 | — | — | EP | claimed |
| WO-2006092691-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN | PFIZER LIMITED (GB) | 2006-09-08 | — | — | WO | claimed |
| US-20050095292-A1 | Sustained release pharmaceutical compositions | WYETH (US) | 2005-05-05 | — | — | US | claimed |
| EP-1235570-A2 | COMBINATIONS OF (S)-2-(BENZYLAMINO-METHYL)-2,3,8,9,-TETRAHYDRO-7H-1,4-DIOXINO(2,3)-E INDOL-8-ONE AND NEUROLEPTICS | Wyeth (US) | 2002-09-04 | — | — | EP | claimed |
| US-6350773-B1 | Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders | AMERICAN HOME PRODUCTS CORPORATION | 2002-02-26 | — | — | US | claimed |
| WO-2001041750-A2 | COMBINATIONS OF (S)-2-(BENZYLAMINO-METHYL)-2,3,8,9,-TETRAHYDRO-7H-1,4-DIOXINO(2,3)-E INDOL-8-ONE AND NEUROLEPTICS | WYETH (US) | 2001-06-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050095292-A1 | Sustained release pharmaceutical compositions | ADCYAP1R1, ABCB11, SLC10A2 | DRD2 3240/4885DRD4 3941/4885DRD3 3367/4885 |
| US-20150158809-A9 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | CPS1, CA7, NAAA | DRD2 3241/4885DRD4 3217/4885DRD3 2698/4885 |
| US-20140243544-A1 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | CPS1, CA7, NAAA | DRD2 3241/4885DRD4 3217/4885DRD3 2698/4885 |
| US-20090111837-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN | PDE7A, PDE7B, PDE3A | DRD2 3707/4885DRD4 3460/4885DRD3 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.